Denmark· DK-28103734104
Baraclude
A entecavir product containing entecavir, registered in Denmark by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 17 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Entecavir is registered in 17 of 19 countries.
Countries holding a registration under ATC J05AF10 (entecavir), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Entecavir · ATC J05AF10
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of entecavir costs, country by country.
Normalised to the WHO defined daily dose (0.5 mg), the median price runs from $0.20 in United States to $12.37 in Switzerland — a ×61 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Entecavir · price per daily dose (0.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$12.37
- FR France$7.50
- IT Italy$4.93
- US United States$0.20 (acquisition cost)
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- ENTECAVIR
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Denmark (DK)
- ATC code
- J05AF10
- ATC class
- Entecavir
- Defined daily dose
- 0.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28103734104
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
56 interactions on record for entecavir.
Graded by severity as the source publishes them — 56 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Entecavir · interactions on record
56 records
- 56 moderate
Most severe, free to view
- CimetidineA02BA01moderate
- RanitidineA02BA02moderate
- FamotidineA02BA03moderate
- NeomycinA07AA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J05AF10
Entecavir, as other registers publish it.
- CanadaACCEL-ENTECAVIRACCEL PHARMA INC
- CanadaAPO-ENTECAVIRAPOTEX INC
- CanadaAURO-ENTECAVIRAURO PHARMA INC
- FinlandBaracludeBristol-Myers Squibb Pharma EEIG
- FinlandBaracludeAbacus Medicine A/S
- FinlandBaracludeBristol-Myers Squibb Pharma EEIG
- PolandBaracludeBristol-Myers Squibb Pharma EEIG
- PolandBaracludeBristol-Myers Squibb Pharma EEIG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/111bb9b3-2323-4411-afcc-30872810311d GET /v1/drugs/111bb9b3-2323-4411-afcc-30872810311d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "0,5 mg",
"auth_role": "MOD",
"dk_drugid": "28103734104",
"substance": "ENTECAVIR",
"auth_procedure": "Central",
"in_medicinpriser": false,
"registration_date_serial": "38894"
}See everything about entecavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.